Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs

Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice

(2017) Hussam A Murad et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases

(2017) Theerasuk Kawamatawong   Journal of Thoracic Disease

Effect of roflumilast on airway remodelling in a murine model of chronic asthma

(2016) S. W. Kim et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist–Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells

(2015) Brijeshkumar S. Patel et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Roflumilast for asthma: Efficacy findings in mechanism of action studies

(2015) P. Bardin et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Roflumilast for asthma: Weighing the evidence

(2015) E.D. Bateman et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Roflumilast for asthma: Efficacy findings in placebo-controlled studies

(2015) E.O. Meltzer et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease

(2014) Mark A Giembycz et al.   CURRENT OPINION IN PHARMACOLOGY

PDE inhibitors currently in early clinical trials for the treatment of asthma

(2014) Maria Gabriella Matera et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Role of the nitric oxide–soluble guanylyl cyclase pathway in obstructive airway diseases

(2014) Lisa L. Dupont et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Immunological aspects of phosphodiesterase inhibition in the respiratory system

(2013) Juraj Mokry et al.   RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY

The asthma–chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations

(2013) Samuel Louie et al.   Expert Review of Clinical Pharmacology

Selective PDE inhibitors as novel treatments for respiratory diseases

(2012) Clive P Page et al.   CURRENT OPINION IN PHARMACOLOGY

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease

(2011) Klaus F. Rabe   BRITISH JOURNAL OF PHARMACOLOGY

The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

(2010) Armin Hatzelmann et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Tadalafil, a Long-Acting Inhibitor of PDE5, Improves Pulmonary Hemodynamics and Survival Rate of Monocrotaline-Induced Pulmonary Artery Hypertension in Rats

(2009) Fusae Sawamura et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Frontrunners in novel pharmacotherapy of COPD

(2008) P BARNES   CURRENT OPINION IN PHARMACOLOGY

The development of allergic inflammation

(2008) Stephen J. Galli et al.   NATURE